January, 2026
January 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Mostafa Faisal Mohammed: Avatrombopag in Aplastic Anemia
Jan 11, 2026, 03:53

Mostafa Faisal Mohammed: Avatrombopag in Aplastic Anemia

Mostafa Faisal Mohammed Saleh, Associate professor of Clinical Hematology and HSCT at Assiut University, shared on LinkedIn:

“Our recent publication and 1st in 2026 out in Therapeutic advances in Hematology (IF 3.1)

Avatrombopag in Aplastic Anemia – Review

  1.  Scope: 10 studies (2023–2025), diverse AA settings (frontline, R/R, elderly, liver disease)
  2.  Efficacy: ORR 55–85%; CR up to ~30%
  3.  Onset: Rapid responses, typically within 1–2 months
  4.  Clinical benefit: Multilineage recovery, reduced transfusion needs
  5.  After eltrombopag: Responses seen even in EPAG-refractory/intolerant patients
  6.  Safety: Favorable profile; no meaningful hepatotoxicity or clonal evolution reported
  7.  Key advantage: Suitable for patients with liver dysfunction, no dietary restrictions

Bottom line: Avatrombopag is an effective, well-tolerated TPO-RA with growing role in AA across disease stages”

Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence

Authors: Mostafa F. Mohammed Saleh, Abdulrahman Nasiri D, Ahmed Kotb Abdrabou, Alfadil Haroon, Hadeel Samarkandi, Hazza Alzahrani, Mahmoud Aljurf, Ali Alahmari

Mostafa Faisal Mohammed: Avatrombopag in Aplastic Anemia

Read full article here.

Stay updated on the latest scientific advances in the field of aplastic anemia with Hemostasis Today.